At a glance
- Originator Aderis Pharmaceuticals (CEASED)
- Class Neuroprotectants
- Mechanism of Action Adenosine A1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 25 Aug 1998 Preclinical development for Cardiovascular disorders in USA (Unknown route)
- 16 May 1997 New profile
- 16 May 1997 Preclinical development for Undefined in USA (Unknown route)